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Detailed characterization of T cell 
receptor repertoires in Multiple 
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The antigen-specific activation of pathogenic T cells is considered essential in the initi-
ation and maintenance of multiple sclerosis (MS). The site of activation, the differential 
involvement of CD4+, and CD8+ T cells, their functional phenotype, and specificity, are 
important aspects to understand MS pathogenesis. The analysis of clonal expansions of 
brain-infiltrating T cells may reveal local antigen-driven activation or specific brain homing 
and allow the identification of putatively pathogenic T cells. We used high-throughput 
T cell receptor β-chain variable gene (TRBV) sequencing (-seq) of genomic (g)DNA, which 
reflects the quantity and diversity of the TRBV repertoire, to characterize three white 
matter demyelinating lesions with different location and inflammatory activity, and paired 
peripheral blood memory CD4+ and CD8+ T cell pools from a secondary progressive 
(SP)MS patient. Our results revealed an important sharing of clonally expanded T cells 
with identical TRBV sequence (clonotypes) across MS lesions independently of their prox-
imity or inflammatory activity. Comparison with circulating T cells showed that the most 
frequent brain-infiltrating CD8+, but not CD4+ clonotypes were also those with highest 
frequency in the peripheral blood, indicating clonal expansion inside the brain or specific 
brain homing of CD4+ but not CD8+ T cells. Parallel TRBV-seq of complementary (c)
DNA that reflects the activation status of the cells, revealed differences between lesions 
regarding inflammatory activity and appears to facilitate the identification of putatively 
pathogenic T cells in active lesions. Approaches to identify pathogenic T cells in brain 
lesions using TRBV-seq may benefit from focusing on lesions with high inflammatory 
activity and from combining gDNA and cDNA sequencing.
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inTrODUcTiOn
Autoimmune inflammation in early multiple sclerosis (MS) is primarily mediated by adaptive 
immune responses and involves autoreactive T cells and macrophages in patients with demyelinat-
ing pattern I active brain lesions and in addition antibody/complement complexes in patients with 
demyelinating pattern II active lesions (1). The efficacy of therapies targeting B and T cells strongly 
supports a role of these cells in MS pathogenesis (2). Regarding T cells, MS is considered a CD4+ 
T cell-mediated autoimmune disease based on the fact that the HLA-DR15 haplotype is the strongest 
genetic risk factor, that myelin-specific CD4+ T cells are able to induce a demyelinating disease 
similar to MS in several experimental animal models (3) and also to exacerbate the human disease 
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(4). However, the fact that the HLA-class I alleles HLA-A*0301 
and HLA-A*0201 are risk-increasing or protective, respectively 
(5, 6), and the greater abundance and invasiveness of CD8+ 
T cells in acute and chronic MS lesions (7, 8), also support a role 
of these cells in MS.
T cells recognize complexes of specific antigenic peptides and 
autologous HLA molecules through their T cell receptors (TCRs), 
and this recognition can lead to clonal expansions by activation 
and proliferation of antigen-specific T  cells. Analysis of T  cell 
clonal expansions in MS brain tissue can allow the identification 
of T cells that have been activated locally or that have been specifi-
cally attracted to the brain and hence are likely pathogenic. In the 
past, several techniques have been employed for the analysis of 
TCR repertoires including PCR amplification of TCR β-chain 
variable genes (TRBV) and subsequent conventional sequenc-
ing, TCR complementary-determining region 3 (CDR3) length 
spectratyping, single strand conformational polymorphisms or 
flow cytometry-based staining with TRBV-specific monoclonal 
antibodies. Using these approaches, several studies have dem-
onstrated skewed TCR repertoires and also clonal expansions of 
mainly CD8+ T cells with identical TRBV sequence (clonotypes) 
in the peripheral blood, cerebrospinal fluid (CSF), as well as 
brain lesions of MS patients (9–17). However, these techniques 
only permit interrogation of a small fraction of sequences and 
thus are not reliable for characterization of the entire repertoire. 
High-throughput TRBV sequencing (TRBV-seq) (18) overcomes 
this limitation by allowing sequencing of very high number of 
TCRs and enabling the accurate identification and quantification 
of individual clones in complex populations. This technique 
has already been used successfully to measure the renewal of 
the T  cell repertoire in MS patients after autologous stem cell 
transplantation (19), to assess the diversity and overlap of CSF 
and blood T cell repertoires (20, 21), to identify clonotypes that 
are clonally expanded in pattern II MS brain lesions (22), and also 
to compare the TRBV repertoires between brain lesions, CSF, and 
blood from the same MS patients (23).
TRBV sequencing of MS brain lesions that differ in location 
and inflammatory activity and come from a single MS patient 
may facilitate the identification of pathogenic T cells and provide 
information about how lesion location or inflammatory activity 
influence brain-infiltrating TRBV repertoires. Furthermore, 
TRBV-seq of paired peripheral CD4+ and CD8+ memory T cell 
pools allows to assign brain-infiltrating T cells to either CD4+ 
or CD8+ subtypes and to compare their relative representation 
in the two compartments. This step will be useful to address 
the assumed predominant implication of CD8+ T  cells in MS 
pathology as previously suggested (23). Despite the broader use 
of TRBV-seq in various immune conditions including MS, the 
method is still relatively new and technical questions, including 
whether parallel gDNA and cDNA sequencing might improve 
the characterization of TRBV repertoires in brain lesions, remain 
to be addressed. Since each cell should have only one copy of 
the productively rearranged V(D)J gDNA, the number of TRBV 
gDNA sequences should correlate well with cell numbers (24), 
and consequently gDNA TRBV-seq should reflect the quantity 
and overall diversity of the global TRBV repertoire. In addi-
tion, gDNA is very stable, an important feature in the analysis 
of brain tissue that cannot always be frozen immediately after 
death/biopsy. Assuming the expression of multiple copies of 
TRBV mRNA per T cell and that the number of copies reflects 
the activation/functional status of the T cells, i.e., higher number 
of copies in activated and replicating cells (25–28), cDNA TRBV-
seq should be more sensitive and reflect the functional status of 
the cells. Since frozen brain lesions should represent a snapshot of 
the in vivo T cell activity at the time of autopsy/biopsy, TRBV-seq 
of cDNA might facilitate the identification of pathogenic T cells 
in brain lesions. However, the higher vulnerability of RNA to 
degradation might jeopardize cDNA sequencing in frozen brain 
tissue.
In this study, we have characterized by gDNA TRBV-seq the 
TRBV repertoire of three white matter demyelinating MS lesions, 
as well as paired peripheral memory CD4+ and CD8+ T cells. 
The three demyelinating lesions that had different location and 
inflammatory activity, were obtained from a secondary progres-
sive (SP)MS patient with pattern II demyelinating lesions (22), for 
whom we had the unique opportunity to have access to peripheral 
blood mononuclear cells (PBMCs) and CSF cells prior to death 
and also autopsy brain tissue. In order to improve the characteri-
zation of the TRBV repertoire we performed cDNA TRBV-seq of 
the three lesions as well as in vitro expansion of brain-infiltrating 
T cell clones (TCCs) obtained from autologous CSF.
MaTerials anD MeThODs
Patient Material
MS Case 1
The SPMS patient with pattern II demyelinating lesions had pre-
viously been described (22). PBMCs, CSF-derived mononuclear 
cells, and autopsy brain tissue were obtained from this patient as 
previously described (22).
MS Case 2
The SPMS patient with pattern III demyelinating lesions had 
previously been described (22).
Rasmussen Encephalitis (RE) Case
The RE patient had previously been described (29).
Brain-derived mononuclear cells from brain biopsies (MS case 
2 and RE case) were obtained as previously described (30).
The study of MS clinical cases 1 and 2 was approved by the 
Ethik Kommission der Ärztekammer Hamburg, protocol No. 
2758, and informed consent was obtained from the patient or 
relatives. The study of the RE case was approved by the Cantonal 
Ethics Committee Zurich (No. 33-2015), and informed consent 
was obtained accordingly from the parents.
cell isolation, -culture, and generation of 
csF-Derived T cell clones (csF-Tccs)
All cell populations were sorted using a FACSAria™ III (BD 
Biosciences, Franklin Lakes, NJ USA), and only preparations 
with a purity of >95% were used for further experiments. 
Memory CD4+ and CD8+ T cells were sorted from peripheral 
blood after staining with the following antibodies: anti-CD3-PE 
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(Biolegend, San Diego, CA, USA), anti-CD4-APC (eBiosciences, 
San Diego, CA, USA), anti-CD8-Pacific Blue (Biolegend), and 
anti-CD45RO FITC (Biolegend) as previously described (22). 
T  cells expressing specific TRBV families were sorted from 
bulk phytohemagglutinin-expanded CSF T  cells after staining 
with the corresponding TRBV-specific antibodies (Beckman 
Coulter, Nyon, Switzerland), expanded and cloned as previously 
described (22).
Dna/rna extractions and 
retrotranscription
DNA and RNA were extracted from cryopreserved cells and frozen 
brain tissue. DNA extraction was performed with DNeasy blood 
& tissue kit (QIAGEN, Hilden, Germany) according to the manu-
facturer’s instructions. Quantity and purity were measured using 
the NanoDrop ND-1000 spectrophotometer. RNA extraction, 
including a DNAse treatment step, was performed with RNeasy 
Micro (QIAGEN) following manufacturer’s instructions. RNA 
integrity was assessed by capillary electrophoresis (Bioanalyzer, 
Agilent Technologies Inc., Santa Clara, CA, USA). RNA was 
reverse transcribed using RevertAid H minus first strand cDNA 
synthesis kit (Thermo Scientific Fermentas, Vilnius, Lithuania).
TrBV sequencing
TRBV sequencing was performed at Adaptive Biotechnologies 
(Seattle, WA, USA) using the immunoSEQ platform (18). TRBV-
seq survey level, designed to sample <100,000 cells, was used 
to sequence the brain lesions (both gDNA and cDNA) since 
we knew that the number of CD3+ T cells was low [<70 cells/
mm2 (22)], and TRBV-seq deep sequencing, designed to sample 
~200,000–1,000,000 cells, was used to sequence the circulating 
CD4+ and CD8+ memory T cell pools.
TRBV chain expression by CSF-derived, individual, in vitro-
generated (CSF-) TCCs was assessed as previously reported (22). 
TCR gene designations are in accord with IMGT nomenclature 
(ImMunoGeneTics1). Throughout the manuscript clonotype 
refers to T cells with identical TRBV sequence while CSF-TCC 
stands for in vitro-generated T cell clone.
Data and statistical analysis
Data analysis was performed using ImmunoSEQ analyzer. 
Statistical analysis was performed using Graphpad Prism 6 soft-
ware (La Jolla, CA, USA). Correlations were assessed with linear 
regression analysis and the Pearson test. Multiple comparisons 
were assessed by one-way ANOVA with Bonferroni’s correction 
for multiple comparisons. P-values < 0.05 were considered sta-
tistically significant.
resUlTs
Description of Ms lesions
Three white matter demyelinating lesions were identified in 
autopsy brain tissue from a SPMS patient with pattern II demy-
elinating active lesions (22). Lesion (L)I and LIII were in closer 
1 www.IMGT.org (accessed July 22, 2004).
proximity, while LIV was more distant. On the basis of myelin 
degradation products present within the macrophages/microglia, 
lesions were classified as follows: LI: center inactive and edge late 
active, LIII: center late active and edge early active (22), and LIV: 
center inactive and edge early active. In order to facilitate reading 
the manuscript, lesions are named: low-active-LI, medium-
active-LIV, and high-active-LIII (Figure 1A).
comparison of the global TrBV 
repertoires in Demyelinating Brain 
lesions
We analyzed the global TRBV repertoires in the three brain 
lesions by gDNA survey TRBV-seq (18). Sequence information 
is summarized in Table 1, and a complete list of all sequences 
is available in Table S1 in Supplementary Material. Although we 
cannot completely discard that we missed relevant unique reads 
performing survey sequencing instead of deep sequencing in the 
brain lesions, the fact that only around 0.5–0.7% of the productive 
sequences were unique, i.e., they were unique TRBV sequence 
generated by immunosequencing of a given sample (Table  1), 
suggests that most of the sequences were sequenced many times, 
and hence it is unlikely that we missed relevant ones. The diver-
sity and clonality were comparable between the three lesions, 
independently of their location or activity level. A search using 
BLASTP program of the non-redundant protein database2 dem-
onstrated that five CDR3 sequences identified in low-active-LI, 
two in medium-active-LIV and one in high-active-LIII matched 
CDR3 sequences in the database but corresponded to TCRs with 
different -BV and -BJ sequences. Clonotypes shared by the dif-
ferent pairs of lesions as well as correlations of their frequencies 
[correlation coefficient (r) and coefficient of determination (r2)] 
are shown in Figure 1B. The total number of sequences that are 
compared influences the number of clonotypes shared by two 
samples, i.e., the probability to find shared sequences increases 
with the number of sequences that are compared [(31); Figure 
S1A in Supplementary Material]. The number of sequences in 
each sample is called cloneset size. To correct for different clone-
set sizes, the number of shared clonotypes has been divided by 
the product of the intersected cloneset sizes, and these data are 
shown as normalized values in all comparisons. The normalized 
number of shared clonotypes and the correlation of their frequen-
cies do not seem to be affected by the proximity of the lesions 
or their inflammatory activity level (Figure 1B). Fifty clonotypes 
were common to the three lesions, and interestingly several were 
among the most frequent clonotypes in the three lesions (big 
circles Figure 1B; Table 2). Seven of the ten most frequent clo-
notypes in low-active-LI were common to the three lesions, eight 
of the ten most frequent clonotypes in medium-active-LIV and 
nine of those in high-active-LIII (Table 2). The presence in the 
other lesions of the 10 most frequent clonotypes identified in each 
lesion is shown in Table S2 in Supplementary Material. In order to 
estimate better the overlap of the three lesions, we compared the 
TRBV repertoires obtained by sequencing two independent gDNA 
extractions from high-active-LIII (Figure S1B in Supplementary 
2 http://blast.ncbi.nlm.nih.gov (accessed April 23, 2017).
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TaBle 1 | Summary of TRBV sequence information.
Productive sequences (%)* Unique productive 
sequences (%)**
Unique productive 
sequences (#)***
“Diversity” shannon 
entropy****
clonality
Low-active-LI (gDNA) 81.50 0.7527 1,062 8.8686 0.1239
Medium-active-LIV (gDNA) 74.56 0.5425 698 8.6789 0.0994
High-active-LIII (gDNA) 65.89 0.5364 271 7.2071 0.1221
BIOPSY RE (gDNA) 76.59 0.3399 790 6.3813 0.3049
BIOPSY MS 2 (gDNA) 78.44 0.8291 2,054 8.1911 0.2185
MEM-CD4 (gDNA) 81.62 5.2018 22,947 13.0884 0.0967
MEM-CD8 (gDNA) 85.87 0.8038 12,126 8.9509 0.3405
Low-active-LI (cDNA) 90.36 2.1277 92 5.9415 0.1038
Medium-active-LIV (cDNA) 76.59 1.0060 237 7.4685 0.0597
High-active-LIII (cDNA) 95.16 0.0152 115 3.0875 0.6453
*Productive sequences (%) have been calculated as: number of productive sequences/total sequences × 100.
**Unique productive sequences (%) have been calculated as: number of unique productive sequences/total productive sequences × 100.
***Number of unique TRBV sequence generated by immunosequencing of a given sample.
****Shannon entropy is one of the most robust measurements of diversity within a complex data set. Shannon entropy is calculated by summing the frequency of each clonotype 
times the log (base 2) of the same frequency over all productive reads in a sample.
FigUre 1 | Comparison of the global TRBV repertoires in brain lesions and CD4+ and CD8+ peripheral memory T cell pools. (a) Scheme of the three brain lesions 
analyzed in this study. Location and activity levels of the three lesions are also specified. (B,c) Logarithmic scatter plots comparing the number of copies of each 
clonotype identified by gDNA sequencing and infiltrating each pair of brain lesions (B), or infiltrating each lesion and the CD4+ (upper scatters) and CD8+ (lower 
scatters) peripheral memory T cell pools (c). Clonotypes are represented by circles, CD4+ clonotypes by triangles and CD8+ clonotypes by squares. Clonotypes 
not shared between lesions or peripheral pools are shown in gray and shared clonotypes in black. Large symbols represent the 50 clonotypes shared by the three 
lesions. Actual and normalized numbers of shared clonotypes as well as correlation coefficient (r) and coefficient of determination (r2) of their frequencies are shown 
in all scatters. Numbers of clonotypes not shared by the different samples are also shown in parenthesis. (D) Pie charts representing the frequencies of CD4+ (in 
gray), CD8+ (in black) and undetermined, i.e., not identified in the peripheral pools, (white) clonotypes in the global T cell repertoires in each lesion.
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Material). This analysis gave a normalized number of shared 
clonotypes of 0.51, r of 0.91 and r2 of 0.82. Comparison of these 
values with those obtained for the pair comparisons of the three 
lesions suggests a high TRBV sequence overlap between the three 
brain samples. Also, as controls, we analyzed the global TRBV 
repertoires in two additional brain biopsies: one from a patient 
with RE (biopsy RE) and one from a patient with MS (biopsy 
MS case 2). Sequence information is summarized in Table 1. As 
expected, the number of shared clonotypes between the three 
brain lesions and the control brain biopsies was very low and 
did not include any of the 50 clonotypes common to the three 
brain lesions (Figure S1C in Supplementary Material). We also 
analyzed the presence of the 50 T  cell clonotypes common to 
the three brain lesions in peripheral blood of a cohort of 25 MS 
patients and 17 HD that had previously been reported (32) (Table 
S3 in Supplementary Material). The frequency of MS patients, 
who share in their peripheral blood one of these clonotypes, was 
higher than the frequency of HD (Table S3 in Supplementary 
Material). 48% of MS patients have in their peripheral blood at 
least one CD8+ clonotype that is shared by the three demyelinat-
ing lesions and 28% of patients at least one CD4+ clonotype, 
while only 23.5% of HD have at least one CD8+ clonotype in 
their peripheral blood that is shared by the three demyelinating 
lesions, and 11.7% at least one CD4+ clonotype. The fact that the 
TCR repertoire is influenced by the MHC and that MS shows 
a strong association with certain HLA-class II and also -class I 
molecules, suggests that a MHC bias might be behind this higher 
overlap in MS patients. Only 8 of the 50 clonotypes shared by the 
three lesions (16%) were shared by at least one MS patient or HD. 
Two of these shared clonotypes, the CD4+ clonotype-7 and the 
CD8+ clonotype-27, were the most shared clonotypes between 
MS patients but also HD, suggesting that these clonotypes may be 
public TCCs, which are commonly found in donors disregarding 
pathology or MHC background (33). Supporting this idea, these 
clonotypes were frequent in the naïve T cell pools of HD (Table 
S3 in Supplementary Material). Furthermore, when the 50 clono-
types, which are shared by the three lesions, were compared with 
a list of 10,000 public clones previously reported (34), no shared 
clonotype was identified, but interestingly, the CDR3 regions 
of the most shared clonotypes, clonotype-7 and clonotype-27, 
matched two sequences from public clones, although these have 
different -BV and -BJ sequences.
comparison of the global TrBV 
repertoires in Demyelinated Brain lesions 
and Peripheral Memory T cell Pools
In order to explore whether brain infiltrates are primarily CD4+ 
or CD8+ T  cell-derived and how brain-infiltrating T  cells are 
represented in the periphery, we performed gDNA TRBV-seq of 
2 ×  105 purified peripheral memory CD45RO+ CD4+ (mem-
CD4+), and 2 × 105 CD8+ (mem-CD8+) cells. Sequence infor-
mation is summarized in Table 1. As expected, mem-CD8+ cells 
showed lower diversity and higher clonality than mem-CD4+ 
cells. We identified 22,947 CD4+ and 12,126 CD8+ different 
clonotypes. Brain-infiltrating clonotypes that are also present 
in mem-CD4+ or mem-CD8+ T cell pools and correlations of 
their frequencies are shown in Figure 1C. Since the numbers of 
TaBle 2 | Clonotypes shared by the three brain lesions.
CD4+ clonotypes are depicted in red and CD8+ clonotypes in blue.
*Clonotypes identified in the three brain lesions using both gDNA and cDNA sequencing. %, frequency of each clonotype in each sample. Rank, position of the clonotype regarding 
its frequency compared with all clonotypes in the sample. Filled cells, clonotypes ranking among the 10% most frequent clonotypes in each sample.
**Frequency of the 50 clonotypes shared by the three lesions that are among the 10% most frequent clonotypes in each lesion.
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FigUre 2 | Comparison of the global CD4+ and CD8+ TRBV repertoires in brain lesions and their presence in peripheral CD4+ and CD8+-ory T cell pools.  
(a) Logarithmic scatter plots comparing the number of copies of each CD4+ (left scatters), CD8+ (middle scatters), or undetermined (right scatters) clonotypes 
identified by gDNA sequencing and shared by each pair of brain lesions. CD4+ clonotypes are represented by triangles, CD8+ by squares and undetermined 
clonotypes by circles. Clonotypes not shared by lesions are shown in gray and shared ones in black. Large symbols represent clonotypes shared by the three 
lesions. Actual and normalized numbers of shared clonotypes as well as correlation coefficient (r) and coefficient of determination (r2) of their frequencies are shown 
in all scatters. (B) Charts representing the frequencies of CD4+ (in gray), CD8+ (in black), and undetermined, i.e., not identified in the peripheral pools, (in white) 
clonotypes in the global T cell repertoires and shared by each pair of brain lesions. (c) Dot plots comparing the numbers of copies in CD4+ (triangles, left graph) 
and CD8+ (squares, right graph) peripheral memory T cell pools of: all mem-CD4+ and mem-CD8+ peripheral clonotypes (all, white) and peripheral clonotypes also 
present in one, two or the three brain lesions (black). Large symbols represent clonotypes shared by the three lesions. Mean (gray line) and statistical significance 
(*p < 0.05, **p < 0.01, ***p < 0.001, and ****p < 0.0001) are shown. Frequencies of mem-CD4+ and mem-CD8+ clonotypes present in one, two, or three lesions 
are also shown.
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shared clonotypes between brain lesions and the peripheral pools 
are also influenced by the cloneset sizes of the samples (Figure 
S1A in Supplementary Material), these numbers have been 
normalized (Figure  1C). Normalized values were very similar 
for the three lesions and slightly higher for the mem-CD8+ 
pool (Figure 1C). As expected, the number of shared clonotypes 
between these T  cell pools and the control brain biopsies was 
very low (Figure S1C in Supplementary Material). Low-active-LI 
and medium-active-LIV showed higher correlation with mem-
CD8+ than with mem-CD4+ cells and higher correlation than 
high-active-LIII for both T cell pools (Figure 1C). Similar CD4/
CD8 ratios were observed in the three lesions (Figure 1D). From 
the 50 clonotypes common to the three lesions, 40% were CD4+, 
50% CD8+, and 10% undetermined, i.e., not identified in the 
peripheral pools (Table 2). These shared clonotypes were among 
the most frequent clonotypes in the mem-CD8+ but not in the 
mem-CD4+ pool (Figure 1C large symbols). While only 7 of the 
20 CD4+ clonotypes common to the three lesions were among 
the 10% most frequent clonotypes in mem-CD4+, representing 
only 0.37% of all cells; 22 of the 25 CD8+ clonotypes common 
to the three lesions were among the 10% most frequent clono-
types in mem-CD8+, representing 32.3% of all cells (filled cells 
Table 2). Analysis of the 10 most frequent clonotypes identified in 
each lesion also showed a higher overlap with mem-CD8+ than 
with mem-CD4+ cells (Table S2 in Supplementary Material). 
Accordingly, the frequency of the 10 most frequent clonotypes 
in the mem-CD8+ T cell pool that were also identified in lesions 
was higher than in the mem-CD4+ T  cell pool (Table S2 in 
Supplementary Material).
comparison of the cD4+ and cD8+ 
global TrBV repertoires in Demyelinating 
Brain lesions
Next, we analyzed the CD4+ and CD8+ clonotypes shared by 
the different lesions (Figure 2A). The three comparisons showed 
similar normalized numbers of shared CD8+ clonotypes, while 
the low-active-LI/medium-active-LIV lesions shared less CD4+ 
clonotypes (Figure 2A). In the three comparisons, the frequen-
cies of shared CD4+ clonotypes showed higher correlation than 
those of shared CD8+ clonotypes (Figure 2A). The fraction of 
CD4+ and CD8+ clonotypes shared by the different lesions was 
very similar (Figure 2B), with only slightly higher frequency of 
shared CD4+ clonotypes for high-active-LIII/medium-active-
LIV. Clonotypes shared by these two lesions also showed the 
lowest frequency of clonotypes that were not identified in the 
peripheral pools (12.5%), similar to the frequency observed in 
the clonotypes shared by the three lesions (10%, Table 2).
The counts in the peripheral memory T cell pools of brain-
infiltrating clonotypes present in one, two, or three lesions are 
shown in Figure 2C. CD8+ clonotypes, which were present in 
the high-active-LIII and medium-active-LIV, were significantly 
more abundant in the corresponding peripheral memory T cell 
pool, and the significance was even higher for CD8+ clonotypes 
shared by two and three lesions (Figure 2C). This was not the 
case for CD4+ clonotypes. Furthermore, 51% of peripheral 
mem-CD8+ cells were present in one lesion, 39% in two and 
32% in the three lesions, while only 7% of mem-CD4+ cells were 
present in one brain lesion, 3% in two and 0.38% in the three 
brain lesions (Figure 2C). The percentages of mem-CD8+ and 
mem-CD4+ cells present in the brain lesions showed a slightly 
negative correlation with the inflammatory activity of the lesion, 
and accordingly, the lowest percentages were found for high-
active-LIII (Figure 2C).
comparison of the Functional TrBV 
repertoires in Demyelinating Brain 
lesions
As mentioned above, while gDNA TRBV-seq should reflect the 
“global” TRBV repertoires very well, cDNA TRBV-seq might 
provide additional information about the functional status of 
infiltrating T cells. Considering that the lesions analyzed in this 
study have different levels of inflammatory activity and might 
contain different frequencies of active T  cells, we analyzed the 
TRBV repertoires in the three lesions also by cDNA TRBV-seq. 
Sequence information is summarized in Table 1 and the com-
plete list of all sequences is available in Ref. (22) and Table S1 
in Supplementary Material. A search using BLASTP program 
of the non-redundant protein database indicated that none of 
these TRBV sequences matched any sequence in the database. 
Unexpectedly, the number of sequences obtained by cDNA 
sequencing was lower in the three lesions than those obtained 
by gDNA sequencing. Although we only analyzed samples with 
RIN values around 6, the partial RNA degradation, which cannot 
completely be avoided when working with human autopsy brain 
tissue, was most likely responsible for these differences. However, 
the differences associated with the inflammatory activity of the 
lesions and in particular the lowest diversity and highest clonality 
in high-active-LIII support the relevance of the cDNA TRBV-seq 
AB
FigUre 3 | Analysis of TRBV repertoires in brain lesions by cDNA TRBV sequencing. (a,B) Logarithmic scatter plots comparing the number of copies of each 
clonotype identified by gDNA and cDNA sequencing in each brain lesion (a) and the number of copies of each clonotype (cDNA sequencing) infiltrating each pair of 
brain lesions (B). Clonotypes not shared by brain lesions are shown in gray and clonotypes shared by brain lesions in black. Large symbols represent the six 
clonotypes shared by the three lesions. Actual, normalized and expected numbers of shared clonotypes as well as correlation coefficient (r) and coefficient of 
determination (r2) of their frequencies are shown in all scatters. Number of clonotypes not shared by the different samples are also shown in parenthesis.
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data. Comparisons of TRBV repertoires obtained by gDNA and 
cDNA sequencing in the three lesions are shown in Figure 3A. 
Normalized values have been used for these comparisons since 
the numbers of shared clonotypes correlated with the cloneset 
sizes of the samples (Figure S2A in Supplementary Material). As 
foreseeable, the highest normalized number of shared clonotypes 
using both approaches as well as the highest correlation of their 
frequencies were found in the low-active-LI, in which a higher 
frequency of inactive TCCs with similar numbers of TRBV gDNA 
and cDNA copies per cell is expected. Accordingly, the lowest 
number of shared clonotypes and correlation of their frequencies 
were found in the high-active-LIII, in which a higher frequency 
of active TCCs having one TRBV gDNA and several cDNA copies 
per cell is expected.
Clonotypes, which were identified by cDNA TRBV-seq and 
which are shared among the different pairs of lesions as well as 
the correlations of their frequencies are represented in Figure 3B. 
For the first time, no correlation was observed between the num-
bers of shared clonotypes identified by cDNA sequencing and 
the cloneset sizes of the samples (Figure S2B in Supplementary 
Material), and therefore, we did not normalize for cloneset sizes. 
Using the regression line of the correlation between the numbers 
of shared clonotypes in each pair of samples and the product 
of the intersected cloneset sizes obtained by gDNA sequencing 
(Figure S2C in Supplementary Material), we calculated the 
expected number of clonotypes shared between lesions with the 
assumption that TCCs were inactive (one cDNA copy per cell) 
(Figure  3B). The number of common clonotypes, which we 
identified by cDNA sequencing, was lower than the expected 
one for the three comparisons. However, clonotypes shared by 
high-active-LIII/medium-active-LIV, the two lesions most likely 
containing higher numbers of active T cells, showed the highest 
discrepancy between the numbers of expected and observed 
common clonotypes. Regarding the frequencies of clonotypes 
shared by the different lesions, no correlations were found.
Six clonotypes identified by cDNA sequencing were common 
to the three lesions. Four of these six clonotypes were among 
the most frequent clonotypes in high-active-LIII, three in 
medium-active-LIV, and only one in low-active-LI (large circles 
in Figure 3B; Table 2). Three of these six clonotypes were also 
identified in the three lesions by gDNA sequencing (Table 2). The 
presence in the other lesions of the 10 most frequent clonotypes 
identified in each lesion by cDNA-seq is shown in Table S2 in 
Supplementary Material. Interestingly, the 10 most frequent 
TaBle 3 | CSF-derived TCCs.
CD4+ TCCs are depicted in red and CD8+ TCCs in blue.
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clonotypes identified in low-active-LI by c-DNA-seq that were 
also identified by gDNA in brain lesions were all CD8+ (Table S2 
in Supplementary Material).
Only Brain-infiltrating Tccs identified by 
cDna sequencing in active lesions can 
Be In Vitro expanded From the csF
Using monoclonal antibodies specific for the TRBV families 
expressed by the 10 most frequent clonotypes identified by gDNA 
and cDNA sequencing in the three lesions, we sorted previously 
phytohemagglutinin-expanded autologous CSF-infiltrating T cells, 
cloned them by limiting dilution and sequenced the CDR3 
region as previously described (22). Using this approach we have 
generated 34 CSF-TCCs (Table 3). Two of these CSF-TCCs were 
identified also in the mem-CD4 + pool and four in the mem-
CD8+. One of these CSF-derived TCCs, a CD8 +  CSF-TCC, 
was among the clonotypes identified in low-active-LI by gDNA 
sequencing, while 13 CSF-TCCs, 8 CD8+, and 5 CD4+, were 
identified in high-active-LIII by cDNA sequencing. Ten of these 
brain-infiltrating CSF-TCCs have been functionally character-
ized in a previous study (22).
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DiscUssiOn
Clonal T cell expansions in MS brain lesions allow the identifi-
cation of T cells that are assumed to be involved in the disease 
process. The TCR sequence functions as fingerprint for each 
TCC, and TRBV-seq serves as a powerful tool for T cell analysis 
and has already provided important new knowledge about TRBV 
repertoires in MS (19–23). In the present study, we have used 
TRBV-seq of MS brain lesions with different location and inflam-
matory activity and paired circulating memory CD4+ and CD8+ 
T cells to identify putatively pathogenic T cells and to address a 
number of important questions such as how lesion location or 
inflammatory activity influence brain-infiltrating TRBV reper-
toires, whether brain infiltrates are primarily CD4+ or CD8+ 
T cell-derived, and how brain-infiltrating T cells are represented 
in the peripheral memory T  cell compartments. Furthermore, 
we explored whether parallel TRBV-seq of gDNA and cDNA 
improves characterization of TRBV repertoires in autopsy brain 
tissue. It is important to note that the three demyelinating brain 
lesions analyzed in this study were from a single SPMS patient 
with pattern II demyelinating lesions (22), and therefore, one 
may not be able to extrapolate our results to patients with 
other clinical forms of MS or other demyelinating patterns. In 
addition, brain tissue was obtained after the patient had been 
prepared for autologous hematopoietic stem cell transplantation 
with cyclophosphamide and G-CSF, treatments that may affect 
the T cell repertoire (35). Pattern II demyelination is associated 
with macrophages and T cell inflammation, as well as prominent 
deposition of antibody/complement complexes at sites of active 
myelin destruction (1). Pattern II has been the dominant pattern 
in histopathological studies, although it might be overrepresented 
in biopsy cohorts (36). The different location and level of inflam-
matory activity of the three demyelinating lesions allowed us to 
explore the putative contribution of these two factors to T cell 
repertoires.
The global TRBV repertoires analyzed by gDNA TRBV-seq 
showed similar diversity and clonality in the three MS lesions 
as well as a noteworthy overlap, which was not influenced by 
lesion location or activity level, and hence suggests an important 
sharing of clonally expanded clonotypes across MS lesions. Since 
different autologous brain lesions were available only from one 
MS patient and no non-MS control, we cannot discern whether 
the level of overlap is a general feature of tissue-resident, brain-
infiltrating memory T cells, which could also be found in healthy 
donors, whether it is a common feature in brain inflammation, 
or is a characteristic of MS lesions. In a previous study, TCR 
analysis of two brain regions from a RE patient demonstrated 
that 7 of the top 10 CNS-expanded clones matched between the 
two regions (37), suggesting that the sharing of clonotypes across 
brain regions is not a specific feature of MS infiltrates. Regarding 
the pathological relevance of the shared T  cell clonotypes, we 
assume that these clonotypes contain both public clones without 
association with MS, but also some that are most likely disease-
relevant. The relatively low overlap between these clonotypes and 
peripheral T cells in HD as well as the fact that these clonotypes 
were not among the 10,000 reported public TCR sequences 
support our assumption, although further comparison with a 
MHC-matched HD cohort is required. In order to explore these 
putatively relevant shared- and clonally expanded clonotypes 
in more detail and to analyze also whether the overall brain 
infiltrates are primarily CD4+ or CD8+ T  cell-derived, we 
compared these repertoires with those of autologous peripheral 
blood mem-CD8+ and mem-CD4+ T cell pools. In agreement 
with previous studies (7, 8), we found a greater abundance of 
CD8+ clonotypes in the overall TRBV repertoires in the three 
lesions as well as in the clonally expanded and shared clonotypes. 
However, despite the overall low abundance of CD4+ clonotypes, 
several of the most clonally expanded clonotypes shared by the 
three lesions were CD4+. The CD4/CD8 ratios were comparable 
in the three lesions. These CD4/CD8 ratios were higher than 
those found by immunohistochemistry in the same patient (22) 
or reported in other studies (7, 8, 11, 16, 17). The higher clonal 
expansions in the mem-CD8+ compared with the mem-CD4+ 
T cell pool result in a lower number of unique TRBV sequences 
for the same number of cells analyzed. A lower number of unique 
sequences to compare translates into a lower overlap and as a 
result higher frequency of undetermined CD8+ than CD4+ 
clonotypes, i.e., TRBV sequences that were not found in the 
peripheral mem-CD4+ and mem-CD8+ pools and hence could 
not be assigned to either CD4+ or CD8+ T cells. This probably 
explains the difference in the CD4/CD8 ratios. We found a higher 
overlap between the global TRBV repertoires of the three lesions 
and the TRBV repertoire of mem-CD8+ when compared with 
mem-CD4+ T cell pool. Although the normalized numbers of 
common clonotypes between lesions and the two peripheral 
pools were comparable in the three lesions, the high-active-LIII 
showed a lower correlation of its frequencies indicating a rep-
ertoire that is more different from the peripheral one. The most 
frequent CD8+ clonotypes identified in the lesions, and particu-
larly those shared by different lesions, also showed significantly 
higher frequencies in the peripheral blood. This finding suggests 
that clonally expanded CD8+ clonotypes in brain lesions, that 
might include some MAIT CD8+ T cells, most likely derive from 
TCCs that are clonally expanded outside the CNS. Several studies 
have reported a skewed TCR repertoire in the peripheral blood 
of MS patients (9, 13), and this observation is more pronounced 
in the CD8+ compartment (15). However, since clonal CD8+ 
T  cell expansions are also common in healthy individuals and 
have been associated with age, lymphopenic conditions, and 
infection with cytomegalovirus (38–43), it is difficult to estimate 
the putative involvement of these cells in MS pathogenesis. 
Furthermore, after autologous stem cell transplantation, one of 
the most efficacious therapies in MS by resetting the immune 
system, the reestablished CD8+ T cell repertoire contains clones 
already present before treatment, while the CD4+ T cell reper-
toire was reset by newly generated clones (19). Regarding CD4+ 
T  cells, the most frequent clonotypes identified in the global 
TRBV repertoires of brain lesions were not the most frequent in 
the mem-CD4+ peripheral T cell pool suggesting clonal expan-
sions inside the brain or specific recruitment of CD4+ TCCs into 
this organ. This observation supports a putative role of these cells 
in MS pathogenesis, and consistent with this, a very high correla-
tion coefficient of the frequencies of the CD4+ TCCs shared by 
the different brain lesions was observed.
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